Kiniksa Pharmaceuticals International plc Class A Ordinary Shares (KNSA)
Stock · NASDAQ · Health Care
$78.58as of 10/16/2026
Price chart
Active signals
KNSA Signal Track Record
How signals performed across all stocks →What KNSA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +1.5% | 55% | September 18, 2026 |
| Bollinger Band Breakout | 29 | +0.8% | 59% | July 28, 2026 |
| Bollinger Band Breakdown | 21 | +8.4% | 57% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +16.3% | 69% | March 31, 2025 |
| Any 20-session window (baseline) | +3.2% | 60% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigationa…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 366
- Website
- www.kiniksa.com/
Fundamentals
- 1-day range
- $76.88$80.34
- Market cap
- $5.97B
- P/E (trailing)
- 77.33
- P/E (forward)
- 48.10
- EPS (trailing)
- $0.98
- Dividend yield
- —
- Beta
- 0.12
- Avg. volume
- 589.0K
How Kiniksa Pharmaceuticals International plc Class A Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Kiniksa Pharmaceuticals International plc Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
- TVTXTravere Therapeutics Inc. Common Stock$49.6▼ 6.04%Market cap $5.89BP/E —$22.59$68.73
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
- AMRXAmneal Pharmaceuticals Inc. Class A Common Stock$19.18▼ 0.36%Market cap $5.76BP/E 39.88$9.56$21.18
- MIRMMirum Pharmaceuticals Inc. Common Stock$80.14▼ 2.73%Market cap $5.74BP/E —$63.23$130
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
| TVTX Travere Therapeutics Inc. Common Stock | $5.89B | — | $49.6 | ▼ 6.04% | $22.59$68.73 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
| AMRX Amneal Pharmaceuticals Inc. Class A Common Stock | $5.76B | 39.88 | $19.18 | ▼ 0.36% | $9.56$21.18 |
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $5.74B | — | $80.14 | ▼ 2.73% | $63.23$130 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kiniksa Pharmaceuticals (NASDAQ:KNSA): Affordable Growth Backed by Accelerating EarningsChartMill · 10/2/2026
- Kiniksa Pharmaceuticals Has Strong Growth And Little Room For DisappointmentSeekingAlpha · 10/2/2026
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs High Growth Momentum With a Breakout SetupChartMill · 9/28/2026
- Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully ValuedYahoo · 9/23/2026
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) Meets Minervini Trend Template and High-Growth Momentum CriteriaChartMill · 9/23/2026
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines Strong Growth With a High-Quality Technical SetupChartMill · 9/18/2026
- Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's WhyYahoo · 9/17/2026
Insider Activity
Insider Actions →- Megna Michael R · September 3, 2026 · Sale4.6K @ $80.3
- Moat Ross · September 1, 2026 · Option Exercise2.5K
- Moat Ross · September 1, 2026 · Option Exercise1.6K
- Moat Ross · September 1, 2026 · Option Exercise1.7K
- Moat Ross · September 1, 2026 · Option Exercise2.5K
- Moat Ross · September 1, 2026 · Grant37.0K
- Moat Ross · September 1, 2026 · Grant9.3K
- Moat Ross · September 1, 2026 · Tax Withholding4.0K @ $79.28
- Ragosa Mark · September 1, 2026 · Option Exercise2.7K
- Ragosa Mark · September 1, 2026 · Option Exercise1.8K
- Ragosa Mark · September 1, 2026 · Option Exercise1.6K
- Ragosa Mark · September 1, 2026 · Option Exercise3.1K
- Ragosa Mark · September 1, 2026 · Grant31.1K
- Ragosa Mark · September 1, 2026 · Grant7.8K
- Ragosa Mark · September 1, 2026 · Tax Withholding4.4K @ $79.28
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Kiniksa Reports Strong Growth and Accelerating Earnings
Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.
Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.